Oligomerization of BH4-truncated Bcl-XL in solution

被引:4
|
作者
Wang, Youli
Cao, Rong
Liu, Dongxang
Chervin, Adam
Yuan, Jian
An, Jing
Huang, Ziwei
机构
[1] Univ Illinois, Dept Biochem, Urbana, IL 61801 USA
[2] Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA
[3] Univ Illinois, Dept Chem, Urbana, IL 61801 USA
[4] Chemokine Pharmaceut Inc, Raylight Corp, La Jolla, CA 92037 USA
基金
美国国家卫生研究院;
关键词
Bcl-X-L; Bcl-2; BH4; domain; truncated Bcl-X-L; oligomerization; apoptosis;
D O I
10.1016/j.bbrc.2007.07.122
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
BH4 domain is critical for the anti-apoptotic functions of Bcl-2 and Bcl-x(L) and their binding abilities with other members of the Bcl-2 family. The cleavage of the BH4 domain in Bcl-x(L) and Bcl-2 by caspase 1 or 3 converts the anti-apoptotic Bcl-x(L) and Bcl-2 into proapoptotic proteins that potently induce apoptosis. Herein, we report that recombinant BCl-x(L) proteins without N-terminal 61 residues, His(6)-N Delta 6l-BCl-x(L)-C Delta 21 and N Delta 61-BCl-x(L)-C Delta 21, form oligomers in solution, whereas Bcl-x(L)-C Delta 21 exists as a monomer. The oligomerization of the truncated proteins is independent of protein-lipid interaction, protein concentration or the ion strength of the solution. Circular dichroism spectrum shows a significant decrease in the content of alpha-helices upon deletion of N-terminal residues. N Delta 61-Bcl-x(L)-C Delta 21 also loses its heterodimerization capability with the BH3 peptide derived from Bak. This newly acquired property might be linked to its ability to induce apoptosis in cells. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:1006 / 1011
页数:6
相关论文
共 50 条
  • [1] Protein oligomerization mediated by the transmembrane carboxyl terminal domain of Bcl-XL
    Ospina, Angelica
    Lagunas-Martinez, Alfredo
    Pardo, Julian
    Carrodeguas, Jose A.
    FEBS LETTERS, 2011, 585 (19) : 2935 - 2942
  • [2] Non-canonical roles of Bcl-2 and Bcl-xL proteins: relevance of BH4 domain
    Gabellini, Chiara
    Trisciuoglio, Daniela
    Del Bufalo, Donatella
    CARCINOGENESIS, 2017, 38 (06) : 579 - 587
  • [3] Identification of small molecular inhibitors of BH3 and Bcl-xL interaction
    Yuan, JY
    CYTOMETRY, 2002, : 27 - 27
  • [4] Dynamics of the BH3-Only Protein Binding Interface of Bcl-xL
    Liu, Xiaorong
    Beugelsdijk, Alex
    Chen, Jianhan
    BIOPHYSICAL JOURNAL, 2015, 109 (05) : 1049 - 1057
  • [5] Molecular basis of Bcl-xL's target recognition versatility revealed by the structure of Bcl-xL in complex with the BH3 domain of beclin-1
    Feng, Wei
    Huang, Siyi
    Wu, Hao
    Zhang, Mingjie
    JOURNAL OF MOLECULAR BIOLOGY, 2007, 372 (01) : 223 - 235
  • [6] The BH3 domain of Bcl-xS is required for inhibition of the antiapoptotic function of Bcl-xL
    Chang, BS
    Kelekar, A
    Harris, MH
    Harlan, JE
    Fesik, SW
    Thompson, CB
    MOLECULAR AND CELLULAR BIOLOGY, 1999, 19 (10) : 6673 - 6681
  • [7] The solution to membrane conformation change of the apoptotic protein Bcl-xL
    Hill, R. Blake
    Thuduppathy, Guruvasuthevan R.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 231
  • [8] BH4-domain peptide from Bcl-xL exerts anti-apoptotic activity in vivo
    Sugioka, R
    Shimizu, S
    Funatsu, T
    Tamagawa, H
    Sawa, Y
    Kawakami, T
    Tsujimoto, Y
    ONCOGENE, 2003, 22 (52) : 8432 - 8440
  • [9] Delivery of Bcl-XL or its BH4 domain by protein transduction inhibits apoptosis in human islets
    Klein, D
    Ribeiro, MM
    Mendoza, V
    Jayaraman, S
    Kenyon, NS
    Pileggi, A
    Molano, RD
    Inverardi, L
    Ricordi, C
    Pastori, RL
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 323 (02) : 473 - 478
  • [10] BH4-domain peptide from Bcl-xL exerts anti-apoptotic activity in vivo
    Rie Sugioka
    Shigeomi Shimizu
    Toshihiro Funatsu
    Hiroshi Tamagawa
    Yoshiki Sawa
    Toru Kawakami
    Yoshihide Tsujimoto
    Oncogene, 2003, 22 : 8432 - 8440